Qizhi Diao | Medicine and Dentistry | Research Excellence Award

Posted on by Phenomenological Research

Research Excellence Award

Qizhi Diao
Hainan Branch, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, China
Qizhi Diao
Affiliation Shanghai Jiao Tong University
Country China
Designation Professor
Scopus ID 52563308500
Documents 19
Citations 252
h-index 9
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0003-1121-4656

Qizhi Diao is a professor affiliated with the Hainan Branch of Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, China. His academic work has focused on the synthesis of functional nanomaterials, the construction of advanced clinical diagnostic sensors, and the development of nanocarrier-mediated therapeutic systems for biomedical applications. His research activities have contributed to innovations in biosensing technologies, point-of-care diagnostics, CRISPR/Cas-enabled sensing systems, and nanopharmaceutical delivery platforms.[1] Diao has participated in multiple nationally and provincially funded scientific projects related to cancer diagnostics, SARS-CoV-2 detection technologies, and exosome identification systems within nucleic acid assembly frameworks.[2]

Abstract

The academic contributions of Qizhi Diao are associated with interdisciplinary developments in nanomedicine, biosensor engineering, and clinical laboratory technologies. His research has emphasized the design of graphdiyne-based nanostructures, electrochemical sensing systems, nanozyme-assisted diagnostics, and portable point-of-care biosensing platforms. Through projects supported by the National Natural Science Foundation of China and regional scientific agencies, Diao has contributed to the development of technologies for detecting infectious diseases, circulating tumor cells, and gastric cancer biomarkers.[3] His work integrates materials science, clinical diagnostics, and biomedical engineering into translational research frameworks applicable to modern laboratory medicine.

Keywords

Nanomaterials; Graphdiyne; Clinical Diagnostic Sensors; CRISPR/Cas Technology; Electrochemical Biosensors; Nanopharmaceuticals; Targeted Drug Delivery; Nanozymes; Medical Laboratory Technology; Point-of-Care Diagnostics; Biomedical Engineering; Electrochemical Sensing.

Introduction

Recent advancements in biomedical engineering and nanotechnology have accelerated the development of highly sensitive diagnostic platforms and targeted therapeutic systems. Within this scientific context, Qizhi Diao has conducted research aimed at integrating nanomaterial synthesis with clinical laboratory applications. His work has addressed major challenges in biosensing accuracy, rapid pathogen detection, and nanocarrier-mediated therapeutic delivery systems.[4]

Qizhi Diao’s investigations into graphdiyne-based sensing systems and nanozyme catalytic materials have contributed to the broader understanding of electrochemical diagnostics and biosensor miniaturization. His projects have also focused on CRISPR/Cas-mediated detection systems capable of improving diagnostic sensitivity for infectious diseases and cancer-associated biomarkers.[5]

Research Profile

Qizhi Diao has maintained a long-term academic focus on the fabrication of functional nanomaterials, clinical diagnostic sensors, and nanocarrier-mediated drug delivery systems. His institutional affiliations include the Hainan Branch of Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine.[1]

His completed and ongoing projects include:

  • Research on encoding for the identification of plasma exosome subtypes based on confined recognition and amplification systems within nucleic acid assembly frameworks funded by the National Natural Science Foundation of China.
  • Portable sensors for simultaneous detection of multiple gastric cancer biomarkers using CRISPR/Cas technology funded by the Hainan Provincial Health Commission.
  • Point-of-care quantitative detection systems for SARS-CoV-2 nucleic acids using graphdiyne sub-nanosheets supported by the Natural Science Foundation Project of Chongqing.
  • Novel 3D magnetic nanocomposites based on graphdiyne-MOFs for simultaneous capture and chemotherapy of circulating tumor cells in peripheral blood.
  • Development of graphdiyne-based systems for the detection of SARS-CoV-2 antigen biomarkers under emergency biomedical research initiatives.

His scientific profile additionally includes responsibilities as an ISO 15189 medical laboratory accreditation assessor and research review expert for multiple scientific organizations and governmental institutions in China.[6]

Research Contributions

Among Qizhi Diao’s reported scientific contributions is the synthesis of sub-nanoscale graphdiyne materials for the rapid and quantitative detection of Mycobacterium tuberculosis and drug-resistant genes.[7] This work supported the development of fluorescence sensing systems with improved analytical sensitivity and operational simplicity.

He also contributed to the preparation of core-shell nanozymes such as ZrFe-MOF@PtSn exhibiting strong peroxidase-like catalytic properties for biosensing applications. Additionally, his research integrated miRNA-initiated strand displacement amplification with CRISPR/Cas12a amplification strategies, nanozyme catalysis, and machine-learning-assisted electrochemical sensing systems.[8]

Qizhi Diao has further contributed to patents related to electrochemical immunosensors, medical testing oscillation devices, and laboratory inspection equipment. These developments reflect the translational dimension of his work in clinical laboratory technologies.[9]

Publications

Qizhi Diao has published research in internationally recognized journals focusing on nanotechnology, biomedical sensing, and clinical diagnostic systems. His publications explore graphdiyne-based fluorescent sensing platforms for detecting Mycobacterium tuberculosis and drug-resistant genes, nanoparticle-based drug delivery systems for cardiovascular diseases, and nanozyme-assisted biosensing technologies for rapid pathogen detection. He has also contributed to studies on high-porosity carbon electrocatalysts and amino-functionalized carbon nanodots for biomedical applications. His scholarly work integrates nanomaterials, electrochemical sensing, CRISPR/Cas technologies, and translational laboratory medicine, supporting advancements in point-of-care diagnostics, targeted therapeutics, and innovative clinical biosensor development.

Research Impact

The research activities of Qizhi Diao have contributed to interdisciplinary developments linking nanotechnology, laboratory medicine, and biomedical sensing systems. His work on graphdiyne nanostructures and nanozyme catalytic platforms has been associated with improved biosensor sensitivity and enhanced diagnostic performance in infectious disease detection.[10]

According to the provided academic indicators, his research record includes an h-index of 9 and more than 252 citations indexed through Scopus, in addition to reported Web of Science citations exceeding 300.[11] His collaborative work with organizations such as the Chinese Medical Doctor Association and the Chinese Medical Association has also supported laboratory medicine standardization and diagnostic research initiatives.

Award Suitability

The academic profile of Qizhi Diao demonstrates sustained engagement in translational biomedical research, particularly within nanomaterials, biosensors, and clinical diagnostics. His involvement in nationally funded scientific projects, patented technologies, and peer-reviewed publications indicates an active contribution to applied medical research and laboratory innovation.

His combination of scientific output, technical expertise, research leadership, and participation in accreditation and evaluation activities supports consideration for the Research Excellence Award under the International Phenomenological Research Awards framework.

Conclusion

Qizhi Diao has contributed to the advancement of nanotechnology-enabled diagnostic systems and biomedical sensing platforms through interdisciplinary scientific research. His work combines materials engineering, electrochemical sensing, nanozyme catalysis, and clinical laboratory applications into translational biomedical solutions. Through publications, funded research projects, patents, and scientific service roles, he has established a research profile connected to contemporary developments in medical diagnostics and nanomedicine.

References

  1. International Phenomenological Research Awards. (2026). Award nomination application form: Qizhi Diao. https://phenomenologicalresearch.com/
  2. National Natural Science Foundation of China. Research project information related to biomedical sensing and exosome identification systems.
  3. Diao Q. Research projects and biomedical sensing technologies associated with clinical diagnostics and nanomaterials research.
  4. Shanghai Jiao Tong University School of Medicine. Biomedical nanotechnology and laboratory medicine research activities.
  5. CRISPR/Cas biosensing applications in rapid diagnostic systems and molecular detection technologies.
  6. China National Accreditation Service for Conformity Assessment (CNAS). ISO 15189 medical laboratory accreditation activities and technical assessment programs.
  7. Chang F, Huang L, Guo C, Xie G, Li J, Diao Q. (2019). Graphdiyne-Based One-Step DNA Fluorescent Sensing Platform for the Detection of Mycobacterium tuberculosis and Its Drug-Resistant Genes. ACS Applied Materials & Interfaces. https://pubs.acs.org/doi/abs/10.1021/acsami.9b15248
  8. Yang F, Xue J, Wang G, Diao Q. (2022). Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.999404
  9. Chinese patent documentation related to electrochemical immunosensors, laboratory inspection devices, and medical testing technologies.
  10. Feng T, Liao W, Li Z, Sun L, Shi D, Guo C, Huang Y, Wang Y, Cheng J, Li Y, Diao Q. (2017). Heavily Graphitic-Nitrogen Self-doped High-porosity Carbon for the Electrocatalysis of Oxygen Reduction Reaction. Nanoscale Research Letters. https://link.springer.com/article/10.1186/s11671-017-2364-6
  11. Elsevier. (n.d.). Scopus author details: Qizhi Diao, Author ID 52563308500. Scopus. https://www.scopus.com/authid/detail.uri?authorId=52563308500

Dr. Elena Tchetina | Medicine and Dentistry | Excellence in Research Award

Posted on by Phenomenological Research

Dr. Elena Tchetina | Medicine and Dentistry | Excellence in Research  Award 

Leading Scientist at Nasonova Research Institute of Rheumatology | Russia

Dr. Elena Tchetina is a distinguished researcher in medicine and dentistry, recognized for her impactful contributions to molecular biology and rheumatology. Her academic foundation includes advanced training in microbiology, cell biology, and molecular sciences, supporting a strong interdisciplinary approach to biomedical research. She has extensive experience as a leading scientist and principal investigator, contributing to high-level research in immunology and molecular physiology. Her research interests focus on osteoarthritis, rheumatoid arthritis, and osteoporosis, with emphasis on gene expression, metabolic regulation, and biomarker discovery for disease progression and therapeutic response. Dr. Elena Tchetina has produced 53 documents with an h-index of 18 and has received 8,094 citations across 7,863 documents, reflecting her global research influence. Her work advances translational medicine by connecting molecular insights with clinical applications, strengthening innovative strategies for diagnosis, prognosis, and personalized treatment in rheumatic diseases.

Citation Metrics

8000

7000

6000

5000

4000

Citations
8094

Documents
53

h-index
18

View Scopus ProfileView ORCID Record

Featured Publications

Molecular Mechanisms of Osteoarthritis Progression and Cartilage Degeneration

– International Journal of Molecular Sciences

Gene Expression Signatures in Rheumatoid Arthritis and Therapeutic Targets

– Frontiers in Immunology

Biomarkers for Predicting Disease Progression in Osteoarthritis Patients

– Arthritis Research & Therapy

Metabolic Pathways and Inflammation in Joint Disorders

– Journal of Clinical Medicine

Translational Approaches in Rheumatology: From Molecular Insights to Clinical Practice

– Clinical Rheumatology

Franziska Münz | Medicine and Dentistry | Future Science Leader Award

Posted on by Phenomenological Research

Dr. Franziska Münz | Medicine and Dentistry | Future Science Leader Award 

Physician at Universität Heidelberg | Germany

Dr. Franziska Münz is a promising researcher in the field of Medicine and Dentistry, demonstrating strong scientific impact through 10 scholarly documents that have collectively received 97 citations across 88 academic works, alongside an h-index of 5. Her research contributions focus on advancing medical knowledge through evidence-based approaches, particularly in clinically relevant and translational domains. Her work reflects a commitment to improving healthcare outcomes by exploring innovative methodologies and interdisciplinary perspectives. With a growing citation record and consistent publication output, Dr. Franziska Münz shows clear potential as an emerging leader in future scientific advancements. Her research trajectory highlights both quality and influence, positioning her as a valuable contributor to the global medical research community and a strong candidate for recognition under the Future Science Leader Award.

Citation Metrics

100

75

50

25

0

Citations
97

Documents
10

h-index
5

View Scopus Profile

Top 5 Publications

Bing Han | Medicine and Dentistry | Outstanding Scientist Award

Posted on by Phenomenological Research

Dr.Bing Han | Medicine and Dentistry | Outstanding Scientist Award 

Dermatologist at The First Hospital of Jilin University | China

Dr. Bing Han is a medical researcher and clinician specializing in dermatological science with a strong foundation in advanced medical education and academic training. Dr. Bing Han has extensive professional experience integrating clinical practice with translational research, focusing on melanoma, vitiligo, and molecular mechanisms of skin disease progression. The research interests emphasize biomarker discovery, metabolic reprogramming, and therapeutic innovation in dermatology. With 99 scholarly documents, 1,291 citations from 1,231 documents, and an h-index of 22, Dr. Bing Han demonstrates sustained scientific impact and excellence in medical research.

Citation Metrics (Scopus)

1400

1000

600

200

0

Citations
1,291

Documents
99

h-index
22


View Scopus Profile

Featured Publications

Taeyoung Kyong | Medicine and Dentistry | Research Excellence Award

Posted on by Phenomenological Research

Dr. Taeyoung Kyong | Medicine and Dentistry | Research Excellence Award 

Professor at Yonsei University College of Medicine | South Korea

Dr. Taeyoung Kyong is a medical academic and clinician recognized for expertise in hospital medicine and inpatient care. His education and professional training underpin a strong foundation in internal medicine and clinical research. He has extensive experience integrating patient-centered practice with system-based healthcare improvement. His research interests focus on hospitalist-led care models, diabetes management, quality improvement, and digital health applications. Overall, Dr. Taeyoung Kyong’s work reflects a sustained commitment to advancing evidence-based inpatient medicine and healthcare excellence.

View ORCID

Featured Publications

Sun Jong Kim | In Vitro Diagnostics | Science and Technology Pioneer Award

Posted on by Phenomenological Research

Dr. Sun Jong Kim | In Vitro Diagnostics | Science and Technology Pioneer Award 

Researcher at BioFront | South Korea

Dr. Sun Jong Kim is a highly accomplished biotechnology and life sciences professional whose career reflects sustained contributions to in vitro diagnostics, stem cell science, biomolecular research, and translational biomedical innovation. Equipped with a strong academic foundation including bachelor’s, master’s, and doctoral studies in life sciences, Dr. Sun Jong Kim has developed deep expertise in cellular biology, developmental biology, and molecular mechanisms of pluripotency. His professional journey includes senior research and leadership roles across multiple biomedical organizations, where he has guided R&D programs involving the establishment and maintenance of pluripotent stem cell lines, large-scale microalgae production systems, medical device development, and regulatory preparation for diagnostic technologies. He has contributed to the development of human embryonic stem cell resources, in vitro differentiation platforms, and advanced diagnostic systems applied to areas such as oncology, COVID-19 rapid testing, and point-of-care technologies. His industrial leadership also includes oversight of product development pipelines, quality assurance systems, and multidisciplinary research operations, demonstrating an ability to translate scientific results into usable biomedical solutions that directly support clinical and research infrastructures. His research outputs include numerous scientific publications, national and international presentations, and patents in areas such as stem cell culturing techniques, photobioreactors, and biomaterial-based innovations. The measurable impact of his scholarly contribution is represented by 24 citations by 24 documents, 2 indexed documents, and an h-index of 2, reflecting ongoing engagement and recognition within the scientific community. Dr. Sun Jong Kim’s research interests encompass stem cell biology, human cell culture systems, the regulation of self-renewal and differentiation pathways, bioprocess design, clinical diagnostics, and biotechnology commercialization. His work has been supported by significant research grants and has contributed to advancements in both academic discovery and applied biomedical engineering. In addition to laboratory research, he has played a crucial role in the development, certification, and evaluation of diagnostic medical devices aligned with international regulatory standards and real-world clinical needs. Through his ongoing work at Biofront and other institutions, Dr. Sun Jong Kim continues to drive innovation in science and technology, contributing to advancements that support more accurate diagnostics, greater understanding of biological systems, and the modernization of biomedical tools used in healthcare and life science research.

Profile: Scopus

Featured Publications:

Kim, S. J.,(1999). Isolation of developmentally regulated novel genes based on sequence identity and gene expression patterns. Molecules and Cells, 9, 207–218.

Kim, S. J.,(2001). Ovarian expression of melatonin Mel(1) receptor mRNA during mouse development. Molecular Reproduction and Development, 59, 126–132.

Kim, S. J.,(2003). Isolation and culture of human embryonic stem-like cells from abnormal blastocysts. Korean Journal of Fertility and Sterility, 30, 293–301.

Kim, S. J.,(2003). Establishment and maintenance of human embryonic stem cells on STO, a permanently growing cell line. Biology of Reproduction, 69, 2007–2014.

Kim, S. J.,(2004). Establishment of embryonic germ cells from cultured human primordial germ cells and their differentiation into neuronal cells. Molecules and Cells, 17, 309–315.

Kim, S. J.,(2004). Recent advances in human embryonic stem cell research. Journal of the Korean Medical Association, 918–925.

Kim, S. J.,(2004). Effects of type IV collagen and laminin on the cryopreservation of human embryonic stem cells. Stem Cells, 22, 950–961.

Kim, S. J.,(2004). Available human feeder cells for the maintenance of human embryonic stem cells. Reproduction, 128, 727–735.

Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award

Posted on by Phenomenological Research

Dr. Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award 

Medical Oncologist at Hospital 12 de Octubre | Spain

Dr. Javier Baena Espinar is a prominent medical oncology researcher whose work has significantly shaped contemporary understanding of thoracic malignancies, precision oncology, and real-world clinical outcomes. His academic background is grounded in advanced training in health sciences, biomedicine, molecular oncology, immuno-oncology, and cancer biology, supported by multiple postgraduate degrees and specialized certifications that have strengthened his expertise in lung cancer research and evidence-based clinical practice. His professional experience spans leading Spanish healthcare and research institutions, where he has contributed to multidisciplinary oncology teams, national research initiatives, and international collaborative networks focused on improving diagnostic accuracy, treatment personalization, and therapeutic decision-making. His research interests center on non-small cell lung cancer, small cell lung cancer, immune checkpoint inhibitors, next-generation sequencing, biomarker discovery, outcomes research, and the intersection between cancer care and infectious disease vulnerabilities. He has been instrumental in studies evaluating immunotherapy effectiveness, prognostic determinants, molecular profiling, and global registry data, producing findings that support the optimization of treatment strategies and guide clinical standards. With 27 published documents, 884 citations from 800 referencing articles, and an h-index of 11, his scholarly contributions reflect sustained impact and influence across oncology and translational research communities. His work appears in high-impact journals and encompasses both clinical and translational dimensions, bridging innovative scientific methodologies with real-world applicability. Through continuous involvement in international collaborations, multicenter studies, and academic dissemination, he has advanced the understanding of patient outcomes, therapeutic safety, and emerging frontiers in cancer treatment. His research trajectory demonstrates a strong commitment to expanding precision medicine, fostering collaborative research excellence, and improving the clinical management of thoracic cancers. Dr. Javier Baena Espinar’s ongoing contributions highlight his dedication to advancing scientific knowledge, strengthening global oncology evidence, and supporting the evolution of patient-centered cancer care.

Profile: Scopus | Orcid

Featured Publications:

  • Baena Espinar, J. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials: Pembro-real 5Y registry results. Journal for Immunotherapy of Cancer.

  • Baena Espinar, J., et al. (2025). Clinical utility of combined tissue and plasma next-generation sequencing in treatment-naïve advanced NSCLC. JTO Clinical and Research Reports.

  • Baena Espinar, J., et al. (2025). Efficacy and safety of lorlatinib in ALK- and ROS1-rearranged metastatic NSCLC within the compassionate use program in Spain.

  • Baena Espinar, J., et al. (2025). Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in lung cancer patients.

  • Baena Espinar, J., et al. (2025). Safety and efficacy of immune checkpoint therapy in patients with cardiac metastasis: A multicenter international retrospective analysis.

  • Baena Espinar, J., et al. (2025). Unmet needs in maintenance therapy for extensive-stage small cell lung cancer.

  • Baena Espinar, J. (2024). Consolidation osimertinib vs durvalumab vs observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Real-world data of first-line cemiplimab monotherapy for PD-L1 high NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage SCLC. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Targeting KRAS G12C in NSCLC: Current standards and developments. Drugs.

  • Baena Espinar, J.(2023). Future perspectives in second-line therapy for non-oncogene–addicted NSCLC. Cancers.

  • Baena Espinar, J. (2023). Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer. Journal of Clinical Oncology.

  • Baena Espinar, J.(2022). Updated prognostication system for thoracic malignancies with COVID-19: TERAVOLT registry. Journal of Thoracic Oncology.

  • Baena Espinar, J. (2022). COVID-19 outcomes, vaccination status, and cancer-related delays during the Omicron wave: TERAVOLT analysis. JTO Clinical and Research Reports.

Tom Schimanski | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Mr. Tom Schimanski | Medicine and Dentistry | Best Researcher Award  

Student at Universität Regensburg | Germany

Mr. Tom Schimanski is an emerging researcher at Universität Regensburg whose work bridges the intersection of medicine, surgery and biomedical innovation. His academic background reflects an early commitment to scientific rigor and medical advancement, culminating in advanced studies and a doctoral research focus within the Department of Plastic, Hand, and Reconstructive Surgery. Building upon a foundation of clinical training, he has developed extensive expertise in translational medicine, integrating laboratory research with real-world surgical applications. His scholarly engagement is marked by active participation in experimental studies addressing tissue regeneration, cellular responses, and cryopreservation methodologies for adipose and connective tissues. Mr. Tom Schimanski’s contributions to the scientific community are evident through his publications in internationally indexed journals such as Cells, where his research explores mechanisms of ferroptosis, biocompatibility of anesthetics, exosome mediated cellular communication, and innovative imaging approaches like multispectral optoacoustic tomography. With 3 published documents, 1 citation, and an h-index of 1, he exemplifies the diligence and precision of a young scientist dedicated to building a lasting impact in medical science. His ongoing collaborations with institutions such as Helmholtz Zentrum München further strengthen his multidisciplinary approach, combining cellular biology, materials science, and reconstructive medicine. Mr. Tom Schimanski’s research interests encompass tissue engineering, regenerative medicine, biomaterials development, and translational surgery, focusing on developing clinically viable strategies to enhance wound healing and graft preservation. His work also reflects a broader vision for integrating biotechnological innovations into surgical practice, fostering advancements that align patient safety with scientific discovery. Through his deep engagement in both experimental and clinical contexts, he continues to advance methodologies that could redefine regenerative outcomes and improve the sustainability of reconstructive procedures. With a growing research record and a strong foundation in evidence-based medicine, Mr. Tom Schimanski represents a new generation of clinician-scientists whose contributions are shaping the evolving landscape of biomedical research and surgical innovation. His pursuit of excellence underscores a commitment to translating science into tangible medical progress, marking him as a promising and impactful figure in contemporary medical research.

Profile: Scopus | Orcid

Featured Publications:

Schimanski, T., Loucas, R., Loucas, M., Brébant, V., Anker, A., Klein, S., Diesch, S. T., Pagani, A., & Prantl, L. (2025). Histological and immunohistochemical characteristics of mechanically processed adipose tissue A systematic review and meta-analysis. Cells, 14(21), 1664.

Schimanski, T., Prantl, L., Eigenberger, A., Felthaus, O., Loucas, R., Utpatel, K., & Steer, K. (2025). CELTPLUS fat increases the metabolic activity as well as the SVF-yield significantly when compared to CELT fat, even after cryopreservation with DMSO. Cells, 14(16), 1270.

Schimanski, T., Loucas, R., Loucas, M., Felthaus, O., Brébant, V., Klein, S., Anker, A., Frank, K., Siegmund, A., Pagani, A., & Prantl, L. (2025). Histology and immunohistochemistry of adipose tissue: A scoping review on staining methods and their informative value. Cells, 14(12), 898.

Eigenberger, A., Felthaus, O., Bartsch, A., Schimanski, T., Utpatel, K., & Prantl, L. (2025). The influence of sedimentation on the composition of the lipoaspirate and the effects on further mechanical processing. Cells, 14(8), 601.

Iker Alonso González | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Mr. Iker Alonso González | Medicine and Dentistry | Best Researcher Award 

FACULTATIVO ESPECIALISTA MEDICO-TECNICO EN MICROBIOLOGÍA Y PARASITOLOGÍA at Cruces University Hospital | Spain

Mr. Iker Alonso González is a dedicated researcher and professional in the field of microbiology and clinical parasitology, recognized for his growing contributions to medical and pharmaceutical sciences. He holds a degree in Pharmacy from the University of the Basque Country (UPV/EHU) and has further specialized in Microbiology and Clinical Parasitology at Cruces University Hospital, where he continues to advance his expertise in infectious disease research and diagnostics. His professional experience at Osakidetza the Basque Health Service combines clinical practice with applied research, focusing on microbial resistance, infectious disease control, and antibiotic stewardship. He has presented numerous research communications, including fourteen posters and two oral presentations at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), addressing critical topics such as antimicrobial resistance patterns in Shigella spp. and the clinical impact of post-treatment uroculture interventions. His scientific publication, “Multiresistant Aeromonas hydrophila bacteremia,” published in Enferm Infecc Microbiol Clin (Engl Ed), reflects his analytical approach and contribution to understanding emerging multidrug-resistant pathogens. His current research interests center around the development of evidence-based antimicrobial protocols, optimization of laboratory diagnostics, and epidemiological monitoring of infectious diseases in clinical settings. Mr. Iker Alonso González’s participation in national research forums and professional societies highlights his commitment to academic collaboration and scientific advancement. His early scholarly impact is reflected in his record of 2 citations by 2 documents, 3 published works, and an h-index of 1, indicating a promising trajectory in medical research. He is also engaged in continuous professional development, ensuring alignment with global standards in clinical microbiology and pharmaceutical practice. Through his rigorous research, clinical application, and scholarly engagement, Mr. Iker Alonso González exemplifies the integration of scientific inquiry and healthcare innovation, contributing to the ongoing efforts to enhance antimicrobial stewardship and patient outcomes in contemporary medicine.

Profile: Scopus

Featured Publications:

  • Alonso-González, I. (2025). Upper limb abscess due to an unusual Clostridium species in an immunocompetent child. Enfermedades Infecciosas y Microbiología Clínica.

  • Alonso-González, I. (2023). Sensitivity profile of Shigella spp. isolates in patients with travelers’ diarrhea in a tertiary hospital in the period 2017–2022. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2023). Impact of a PROA intervention on the request of non-proven post-treatment control urocultures. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2022). Multiresistant Aeromonas hydrophila bacteremia. Enfermedades Infecciosas y Microbiología Clínica

 

Barbara Ariue | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Dr. Barbara Ariue | Medicine and Dentistry | Best Researcher Award 

Dr. Barbara Ariue is a distinguished medical professional and academic leader specializing in pediatric allergy and immunology, recognized for her outstanding contributions to research, education, and clinical innovation. As an Associate Professor of Pediatrics at a leading medical institution, she has dedicated her career to advancing the understanding and management of pediatric asthma, allergic conditions, stinging insect allergies, and immunodeficiency disorders. Her academic journey reflects a deep commitment to excellence in both teaching and scientific inquiry, inspiring medical students and resident physicians to pursue evidence-based and compassionate patient care. Dr. Barbara Ariue’s research has significantly impacted the field, particularly through her pioneering project, “Addressing Knowledge Gaps in Diagnosing and Managing Inborn Errors of Immunity,” which received a planning grant from the Allergists’ Foundation Community Grant Program under the American College of Allergy, Asthma, and Immunology. The project evaluates diagnostic practices, interdisciplinary collaboration, and educational needs in managing immunodeficiencies, leading to her recent publication, “Lessons from the ACAAI Survey: Advancing the Diagnostic and Therapeutic Strategies for the Practicing Allergist-Immunologist,” in the Annals of Allergy, Asthma, and Immunology. Her scholarly output includes publications in prestigious journals such as Journal of Clinical Immunology, Pediatrics, and Biochemical and Biophysical Research Communications. In addition to her research, she serves as a consultant and advisory board member for various pharmaceutical organizations, contributing her expertise to clinical trials and therapeutic advancements in immunology. Professionally, she holds fellowships and leadership positions in numerous medical societies, including the American College of Allergy, Asthma, and Immunology, and the American Academy of Pediatrics, reflecting her influence in shaping professional standards in allergy and immunology. Her citation index demonstrates 168 citations by 168 documents, with 11 publications and an h-index of 6, underscoring the impact and reach of her scientific work. Dr. Barbara Ariue’s career embodies a balance of clinical dedication, academic leadership, and research excellence, with her contributions continually shaping the future of pediatric immunology and fostering global advancements in medical science and patient care.

Profile: Scopus | Orcid  

Featured Publications:

  • Oh, C. K., Ariue, B., Alban, R. F., Shaw, B., & Cho, S. H. (2002). PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochemical and Biophysical Research Communications, 294(5), 1155–1160.

  • Heimall, J., Keller, M., Saltzman, R., Bunin, N., McDonald-McGinn, D., Ariue, B., … Markert, M. L. (2012). Diagnosis of 22q11.2 deletion syndrome and Artemis deficiency in two children with T-B-NK+ immunodeficiency. Journal of Clinical Immunology, 32(5), 1141–1144.

  • Cho, S. H., Hall, I. P., Wheatley, A., Ariue, B. K., Abraha, D., Delmundo, J., & Oh, C. K. (2001). The possible role of plasminogen activator inhibitor-1 gene in the development of asthma. Journal of Allergy and Clinical Immunology, 107.

  • Ariue, B. K., Cho, S. H., Tam, S. W., & Oh, C. K. (2001). 142 Analysis of airway remodeling genes in human mast cells by cDNA microarrays. Journal of Allergy and Clinical Immunology, 107.

  • Ariue, B. K. & Oh, C. K. (2005). Chapter 43 – Anaphylaxis (in book chapter). In Pediatrics. Mosby Inc.

  • Ariue, B. K. & Oh, C. K. (2005). Chapter 48 – Insect allergies (in book chapter). In Pediatrics. Mosby Inc.

  • McDonnell, J., Angarola, B., Ariue, B., Arnold, D. E., Assa’ad, A. H., Aytekin, C., … Bleesing, J. (2024). COVID-19 vaccination in patients with inborn errors of immunity reduces hospitalization and critical care needs: a USIDNET report. Journal of Clinical Immunology.